Recent developments in leishmaniasis: Epidemiology, diagnosis, and treatment

Current Infectious Disease Reports

Volumn 7, Issue 1, 2005, Pages 33-38

  Berman, Jonathan ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; CREATININE; FLUCONAZOLE; GENERIC DRUG; LIVER ENZYME; MEGLUMINE ANTIMONATE; METHYLBENZETHONIUM CHLORIDE; MILTEFOSINE; PAROMOMYCIN; PLACEBO; STIBOGLUCONATE SODIUM;

ADOLESCENT; ADULT; AFGHANISTAN; ARTICLE; CELLULAR IMMUNITY; CHILD; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; CREATININE BLOOD LEVEL; DIARRHEA; DRUG COST; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FORMULATION; DRUG TOLERANCE; ENDEMIC DISEASE; ENVIRONMENTAL PROTECTION; ETHNIC DIFFERENCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY FUNCTION TEST; LEISHMANIA MAJOR; LEISHMANIA TROPICA; LEISHMANIASIS; LIVER FUNCTION TEST; MICROBIOLOGICAL EXAMINATION; MICROSCOPY; NAUSEA; PNEUMONIA; POLITICS; POLYMERASE CHAIN REACTION; REFUGEE; RELAPSE; RISK ASSESSMENT; SHORT COURSE THERAPY; SIDE EFFECT; SKIN TEST; SUDAN; TH1 CELL; TREATMENT OUTCOME; VOMITING;

EID: 13544254608     PISSN: 15233847     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11908-005-0021-1     Document Type: Article

References (30)

1. Irajhi AA, Ibrahim EA, De Vol EB, et al.: Fluconazole for the treatment of cutaneous leishmaniasis caused by Leishmania major. N Engl J Med 2002, 346:891-895.
2. Herwaldt BL, Arana BA, Navin TR: The natural history of cutaneous leishmaniasis in Guatemala. J Infect Dis 1992, 165: 18-527.
3. Navin TR, Arana BA, Arana FE, et al.: Placebo-controlled clinical trial of sodium stibogluconate (Pentostam) versus ketoconazole for treating cutaneous leishmaniasis in Guatemala. J Infect Dis 1992, 165:528-534.
4. Velez I, Agudelo S, Hendrickx E, et al.: Inefficacy of allopurinol for Colombian cutaneous leishmaniasis: a randomized, controlled trial. Ann Intern Med 1997, 126:232-236.
5. Desjeux P: Worldwide increasing risk factors for leishmaniasis. Med Microbiol Immunol 2001, 190:77-79.
6. Reithinger R, Mohsen H, Aadil K, et al.: Anthroponotic cutaneous leishmaniasis Kabul, Afghanistan. Emerg Infect Dis 2003, 9:727-729.
7. Centers for Disease Control and Prevention: Update: cutaneous leishmaniasis in US military personnel - Southwest/Central Asia, 2002-2004. MMWR Morb Mortal Wkly Rep 2004, 53: 64-265.
8. Davies CR, Reithinger R, Campbell-Lendrum D, et al.: The epidemiology and control of leishmaniasis in Andean countries. Cad Saude Publica 2000, 16:925-950.
9. Ramirez JR, Adugelo S, Muskus C, et al.: Diagnosis of cutaneous leishmaniasis in Colombia: the sampling site within lesions influences the sensitivity of parasitological diagnosis. J Clin Microbiol 2000, 38:3768-3773.
10. Weigle KA, labrada LA, Lozano C, et al.: PCR-based diagnosis of acute and chronic cutaneous leishmaniasis caused by Leishmania (viannia). J Clin Microbiol 2002, 40:601-606.
11. de Oliveira CI, Bafica A, Oliveira F, et al.: Clinical utility of polymerase chain reaction-based detection of Leishmania in the diagnosis of American cutaneous leishmaniasis. Clin Infect Dis 2003, 37:e149-e153.
12. Rodrigues EH, Felinto de Brito ME, Mendonca MG, et al.: Evaluation of PCR for diagnosis of American cutaneous leishmaniasis in an area of endemicity in northeastern Brazil. J Clin Microbiol 2002, 40:3572-3576.
13. Faber WR, Oskam L, van Gool T, et al.: Value of diagnostic techniques for cutaneous leishmaniasis. J Am Acad Dermatol 2003, 49:70-74.
14. Mendonca MG, de Brito ME, Rodrigues EH, et al.: Persistence of leishmania parasites in scars after clinical cure of American cutaneous leishmaniasis: is there a sterile cure? J Infect Dis 2004, 189:1018-1023.
15. Thakur CP, Kanyok TP, Pandey AK, et al.: Treatment of visceral leishmaniasis with injectable paromomycin (aminosidine). An open-label randomized phase-II clinical study. Trans R Soc Trop Med Hyg 2000, 94:432-433.
16. Veeken H, Ritmeijer K, Seaman J, Davidson R: A randomized comparison of branded sodium stibogluconate and generic sodium stibogluconate for the treatment of visceral leishmaniasis under field conditions in Sudan. Trop Med Int Health 2000, 5:312-317.
17. Moore E, O'Flaherty D, Heuvelmans H, et al.: Comparison of generic and proprietary sodium stibogluconate for the treatment of visceral leishmaniasis in Kenya. Bull World Health Organ 2001, 79:388-393.
18. Ritmeijer K, Veeken H, Melaku Y, et al.: Ethiopian visceral leishmaniasis: generic and proprietary sodium stibogluconate are equivalent; HIV co-infected patients have a poor outcome. Trans R Soc Trop Med Hyg 2001, 95:668-672.
19. Sundar S, Jha TK, Thakur CP, et al.: Low-dose liposomal amphotericin B in refractory Indian visceral leishmaniasis: a multicenter study. Am J Trop Med Hyg 2002, 66:143-146.
20. Sundar S, Jha TK, Thakur CP, et al.: Oral miltefosine for Indian visceral leishmaniasis. N Engl J Med 2002, 347:1739-1746.
21. Bhattacharya SK, Jha TK, Sundar S, et al.: Efficacy and tolerability of miltefosine for childhood visceral leishmaniasis in India. Clin Infect Dis 2004, 38:217-221.
22. Romero GA, Guerra MV, Paes MG, Macedo VO: Comparison of cutaneous leishmaniasis due to L. braziliensis and L. guyanensis in Brazil: therapeutic response to meglumine antimoniate. Am J Rop Med Hyg 2001, 65:456-465.
23. Machado, P, Araujo C, da Silva AT, et al.: Failure of early treatment of cutaneous leishmaniasis in preventing the development of an ulcer. Clin Infect Dis 2002, 34:e69-e73.
24. Palacios R, Osorio LE, Grajalew LF, Ochoa MT: Treatment failure in children in a randomized clinical trial with 10 and 20 days of meglumine antimonate for cutaneous leishmaniasis due to Leishmania viannia species. Am J Trop Med Hyg 2001, 64:187-193.
25. Wortmann G, Miller RS, Oster C, et al.: A randomized, double-blind study of the efficacy of a 10- or 20-day course of sodium stibogluconate for treatment of cutaneous leishmaniasis in United States military personnel. Clin Infect Dis 2002, 35: 61-267.
26. Soto JM, Toledo JT, Gutierrez P, et al.: Treatment of cutaneous leishmaniasis with a topical antileishmanial drug (WR279396): phase 2 pilot study. Am J Trop Med Hyg 2002, 66: 47-151.
27. Arana BA, Mendoza CE, Rizzo NR, Kroeger A: Randomized, controlled, double-blind trial of topical treatment of cutaneous leishmaniasis with paromomycin plus methylbenzethonium chloride ointment in Guatemala. Am J Trop Med Hyg 2001, 65:466-470.
28. Soto J, Fuya P, Herrera R, Berman J: Topical paromomycin/MBCL plus parenteral meglumine in the treatment of American cutaneous leishmaniasis: a controlled study. Clin Infect Dis 1998, 26:56-58.
29. Soto J, Toledo J, Gutierrez P, et al.: Treatment of American cutaneous leishmaniasis with miltefosine, an oral agent. Clin Infect Dis 2001, 33:E57-E61.
30. Soto J, Arana BA, Toledo J, et al.: Miltefosine for New World cutaneous leishmaniasis. Clin Infect Dis 2004, 38: 266-1272.